company background image
OBSV

ObsEva NasdaqGS:OBSV Stock Report

Last Price

US$0.14

Market Cap

US$14.3m

7D

0.8%

1Y

-95.4%

Updated

01 Oct, 2022

Data

Company Financials +
OBSV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

OBSV Stock Overview

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy.

ObsEva SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ObsEva
Historical stock prices
Current Share PriceUS$0.14
52 Week HighUS$3.09
52 Week LowUS$0.13
Beta0.28
1 Month Change-19.99%
3 Month Change-91.93%
1 Year Change-95.42%
3 Year Change-98.08%
5 Year Change-98.37%
Change since IPO-98.78%

Recent News & Updates

Aug 22

ObsEva stock dips on Nasdaq non-compliance notice

ObsEva SA (NASDAQ:OBSV) received a notice from Nasdaq for failing to comply with the rule of maintaining a minimum of $10M in stockholders' equity for continued listing on the exchange. The company had disclosed in a SEC filing that as of June 30, it had shareholders' equity of ~$2.10M. ObsEva has until Aug. 29 to submit a plan to regain compliance after Nasdaq decided to provide a shortened response time to the company. The company said it intends to submit plan by the date. On July 27, ObsEva stock fell ~78% on plans to restructure following setback for uterine fibroids drug. Earlier in August, the company said it was retiring $31M in debt and had announced $11M debt refinancing. OBSV -4.13% to $0.23 premarket Aug. 22

Aug 01

ObsEva to retire $31M in debt and announces $11M debt refinancing

ObsEva (NASDAQ:OBSV) announced the early retirement of $31M in debt partially owed to certain funds and accounts managed by JGB Management post its securities purchase agreement. The company has also entered into an amendment and forbearance agreement with respect to the outstanding debt held by JGB. Under agreement terms, ObsEva and JGB agreed to apply the $31M cash earlier held as collateral in a control account against the outstanding convertible notes on a pro rata basis, with JGB waiving a 25% prepayment penalty on the early debt retirement. JGB has agreed to forbear for a period of up to three months from enforcing any rights or remedies under the notes. In exchange, $1.5M was added to the outstanding principal balance under the notes, leading to ~$11M of convertible notes outstanding, and the conversion price of the notes was adjusted to a conversion price of $0.26/share. Shares trading 1.6% higher premarket.

Shareholder Returns

OBSVUS BiotechsUS Market
7D0.8%0.4%-2.5%
1Y-95.4%-25.6%-23.2%

Return vs Industry: OBSV underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: OBSV underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is OBSV's price volatile compared to industry and market?
OBSV volatility
OBSV Average Weekly Movement25.4%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: OBSV is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: OBSV's weekly volatility has increased from 15% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201248Brian O'Callaghanhttps://www.obseva.com

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization.

ObsEva SA Fundamentals Summary

How do ObsEva's earnings and revenue compare to its market cap?
OBSV fundamental statistics
Market CapUS$14.34m
Earnings (TTM)-US$63.83m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OBSV income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$63.83m
Earnings-US$63.83m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.63
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-1,565.5%

How did OBSV perform over the long term?

See historical performance and comparison